Cranberry extract
Vaccinium macrocarpon · berry, standardised to 30 percent proanthocyanidin · UTI Herbal Blend ·
amount not published
The one ingredient on this panel with a strong positive systematic review behind it.
The 2023 Cochrane review pooled 50 randomised trials across 8,857 participants and found cranberry products reduced symptomatic, culture-verified urinary tract infection overall, with a risk ratio of 0.70, and in women with recurrent infection specifically. A 2017 meta-analysis restricted to otherwise healthy women agreed. That is a genuinely good evidence base and it is the reason this panel is not a waste of money. Two caveats belong beside it. The same Cochrane review found no demonstrable difference between low, moderate and high proanthocyanidin doses, which undercuts any marketing angle built on standardisation percentages. And it found little or no benefit in elderly institutionalised people, in pregnancy, or where the bladder does not empty properly. NCCIH puts the effect at around 25 percent in the women where it works, and states plainly that cranberry is not a substitute for treating an infection that already exists.
Bearberry
Arctostaphylos uva-ursi · leaf · UTI Herbal Blend ·
amount not published
A traditional urinary herb with two randomised trials, and neither of them went the way the category would like.
Two randomised trials have tested uva-ursi in women with uncomplicated urinary tract infection and both are unflattering. REGATTA randomised 398 women against fosfomycin: uva-ursi cut antibiotic courses by 64 percent, but it failed non-inferiority on symptom burden and produced more pyelonephritis, eight cases against two. ATAFUTI randomised 382 women and found no benefit on frequency symptoms at all and no significant reduction in antibiotic use. The duration limit traditionally placed on bearberry comes from its chemistry rather than from those trials: arbutin is converted and excreted in urine largely as hydroquinone, and one crossover study recovered about 65 percent of an oral dose that way. A published risk assessment concludes ordinary short-term doses stay well inside safe exposure limits, and you should know that all three of its authors worked for a bearberry product manufacturer, and that it addresses short-term use only. Daily use for six months is not what it assessed.
Berberine hydrochloride
granular extract, 8 percent · bark and root · UTI Herbal Blend ·
amount not published
Pharmacologically real, poorly absorbed, and the item on this panel most likely to interfere with a prescription.
Berberine is the item on this panel with the most pharmacology and the least relevance to the urinary tract. Its oral bioavailability is under one percent, which sounds disqualifying until you notice that it is nonetheless active by mouth: the best meta-analysis of berberine randomised trials is about blood lipids, and it shows real effects. That is the problem. The strongest human evidence for berberine is for something this product is not sold for, and there is no comparable synthesis for bladder, urinary or vaginal outcomes. What does travel is the interaction profile, and it travels whether the ingredient helps or not: berberine inhibits CYP3A4 and P-glycoprotein, it raised ciclosporin exposure by 19 percent in a small human study, and a 2025 crossover trial found a dose-dependent interaction with metformin using a berberine-containing plant. This is the ingredient that makes a pharmacist's opinion worth getting.
Mimosa pudica seed extract
Mimosa pudica · seed · UTI Herbal Blend ·
amount not published
Listed first on the panel and supported by nothing that was done in a person.
It is listed first on the panel, which usually signals the largest share of the blend, and there is no human trial behind it for any urinary, bladder, vaginal or digestive outcome. We looked. The published record is an in vitro study from 1990 in which leaf extract inactivated parasite larvae in a petri dish, an in vivo study in experimentally infected chickens, and a review of the seed mucilage as a pharmaceutical excipient that describes it as biocompatible and non-toxic and reports no health effect of any kind. Note that the first of those used leaf, and this label specifies seed. Traditional use is a real thing and it is not nothing, but the FTC is explicit that traditional-use claims still require scientific backing or a clear statement that it is absent. This is that statement.
The five lactobacillus strains
Lactobacillus crispatus, acidophilus, plantarum, gasseri, casei · probiotic blend, 50 mg in total · Probiotic Blend ·
amount not published
The half of the formula the sales page leads with, carrying the smaller of the two blend totals.
Five strains in 50 mg, and the honest summary is that the clinical case is not made. The Cochrane review of probiotics for preventing urinary tract infection pooled nine trials in 735 people and found no significant reduction, a risk ratio of 0.82 with a confidence interval from 0.60 to 1.12, with most studies at high risk of bias. The best trial of the headline strain, Stapleton and colleagues in 100 premenopausal women, found recurrence in 15 percent on L. crispatus against 27 percent on placebo, which sounds good until you read the interval: 0.2 to 1.2, crossing 1, not statistically significant. The one unambiguously positive randomised result, Cohen and colleagues in the New England Journal of Medicine, was for bacterial vaginosis rather than urinary infection. And both of those trials delivered L. crispatus intravaginally, as a suppository. This is a capsule you swallow, and a result obtained by one route does not transfer to another. The underlying biology is sound: most healthy vaginal communities are lactobacillus-dominated, and L. crispatus is one of the species that does it. Sound biology is where medicine starts, not where it finishes. The two strain codes printed here, LCr86 and N13, have no trial record we could find under those designations at all.
